
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Дек. 17, 2024
In recent years, tumor immunotherapy has become an active research area, with the emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical evidence indicates that programmed cell death protein 1 (PD-1) monoclonal antibodies and other drugs have remarkable therapeutic effects. V-domain Ig suppressor T-cell activation (VISTA) is a new type receptor highly expressed in various tumors. It co-expressed PD-1, immunoglobulin domain, mucin domain-3 (Tim-3), immunoglobulin, immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) associated prognosis, which suggests it may be target for As no mature drugs, VISTA acute myeloid leukemia (AML), multiple myeloma (MM), hematological malignancies; however, its pathogenic mechanism should defined to better guide treatment.
Язык: Английский